Monopar Therapeutics Inc
NASDAQ:MNPR

Watchlist Manager
Monopar Therapeutics Inc Logo
Monopar Therapeutics Inc
NASDAQ:MNPR
Watchlist
Price: 36.9 USD Market Closed
Market Cap: 225.5m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

MNPR Price Targets Summary
Monopar Therapeutics Inc

Wall Street analysts forecast MNPR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MNPR is 59.84 USD with a low forecast of 40.4 USD and a high forecast of 79.8 USD.

MNPR Lowest Forecast
Wall Street Target
40.4 USD
9% Upside
MNPR Average Forecast
Wall Street Target
59.84 USD
62% Upside
MNPR Highest Forecast
Wall Street Target
79.8 USD
116% Upside
Lowest
Price Target
40.4 USD
9% Upside
Average
Price Target
59.84 USD
62% Upside
Highest
Price Target
79.8 USD
116% Upside
Monopar Therapeutics Inc Competitors:
Price Targets
CPRX
Catalyst Pharmaceuticals Inc
41% Upside
GYRE
Gyre Therapeutics Inc
79% Upside
1801
Innovent Biologics Inc
8% Upside
BMRN
Biomarin Pharmaceutical Inc
63% Upside
CPRX
Catalyst Pharmaceuticals Inc
41% Upside
GYRE
Gyre Therapeutics Inc
79% Upside
1801
Innovent Biologics Inc
8% Upside
BMRN
Biomarin Pharmaceutical Inc
63% Upside
ELUT
Elutia Inc
404% Upside
MDGL
Madrigal Pharmaceuticals Inc
47% Upside
B
251120
Bio-FD&C Co Ltd
33% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
14% Upside

Revenue
Forecast

Revenue Estimate
Monopar Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Monopar Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Monopar Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-59%
Average Miss
What are analyst estimates?

See Also

Summary
MNPR intrinsic value, competitors valuation, and company profile.
DCF Valuation
MNPR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MNPR stock valuation using valuation multiples.
Wall Street Estimates
MNPR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MNPR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MNPR's stock price target?
Price Target
59.84 USD

According to Wall Street analysts, the average 1-year price target for MNPR is 59.84 USD with a low forecast of 40.4 USD and a high forecast of 79.8 USD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.